Short-term longitudinal evaluation of cerebral blood flow in mild Alzheimer's disease

2003 ◽  
Vol 24 (1) ◽  
pp. 24-30 ◽  
Author(s):  
G. Tonini ◽  
M.F. Shanks ◽  
A. Venneri
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Short Term ◽  
Longitudinal Evaluation

scholarly journals Increasing cerebral blood flow improves cognition into late stages in Alzheimer’s disease mice

2019 ◽  
Vol 40 (7) ◽  
pp. 1441-1452 ◽  
Author(s):  
Oliver Bracko ◽  
Brendah N Njiru ◽  
Madisen Swallow ◽  
Muhammad Ali ◽  
Mohammad Haft-Javaherian ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Short Term Memory ◽  
Memory Function ◽  
Neutrophil Adhesion ◽  
Short Term ◽  
Term Memory ◽  
Model Of Alzheimer’S Disease

Alzheimer’s disease is associated with a 20–30% reduction in cerebral blood flow. In the APP/PS1 mouse model of Alzheimer’s disease, inhibiting neutrophil adhesion using an antibody against the neutrophil specific protein Ly6G was recently shown to drive rapid improvements in cerebral blood flow that was accompanied by an improvement in performance on short-term memory tasks. Here, in a longitudinal aging study, we assessed how far into disease development a single injection of anti-Ly6G treatment can acutely improve short-term memory function. We found that APP/PS1 mice as old as 15–16 months had improved performance on the object replacement and Y-maze tests of spatial and working short-term memory, measured at one day after anti-Ly6G treatment. APP/PS1 mice at 17–18 months of age or older did not show acute improvements in cognitive performance, although we did find that capillary stalls were still reduced and cerebral blood flow was still increased by 17% in 21–22-months-old APP/PS1 mice given anti-Ly6G antibody. These data add to the growing body of evidence suggesting that cerebral blood flow reductions are an important contributing factor to the cognitive dysfunction associated with neurodegenerative disease. Thus, interfering with neutrophil adhesion could be a new therapeutic approach for Alzheimer’s disease.

scholarly journals Increasing cerebral blood flow improves cognition into late stages in Alzheimer’s disease mice

2019 ◽  
Author(s):  
Oliver Bracko ◽  
Brendah N. Njiru ◽  
Madisen Swallow ◽  
Muhammad Ali ◽  
Chris B. Schaffer
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Short Term Memory ◽  
Memory Function ◽  
Specific Protein ◽  
Short Term ◽  
Term Memory ◽  
Improved Performance

AbstractAlzheimer’s disease (AD) is associated with a 20-30% reduction in cerebral blood flow. In the APP/PS1 mouse model of AD, inhibiting neutrophil adhesion using an antibody against the neutrophil specific protein Ly6G was recently shown to drive rapid improvements in cerebral blood flow that was accompanied by an improvement in performance on short-term memory tasks. Here, in a longitudinal aging study, we assessed how far into disease development a single injection of anti-Ly6G can acutely improve memory function. We found that APP/PS1 mice as old as 15-16 months had improved performance on the object replacement and Y-maze tests of short-term memory, measured at one day after anti-Ly6G treatment. APP/PS1 mice 17-18 months of age or older did not show acute improvements in cognitive performance, although we did find that cerebral blood flow was still increased by 17% in 21-22 months old APP/PS1 mice given anti-Ly6G. These data add to the growing body of evidence suggesting that cerebral blood flow reductions are an important contributing factor to the cognitive dysfunction associated with neurodegenerative disease.

Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease

2015 ◽  
Vol 12 (10) ◽  
pp. 914-922 ◽  
Author(s):  
Maximilian Wiesmann ◽  
Carmen Capone ◽  
Valerio Zerbi ◽  
Laura Mellendijk ◽  
Arend Heerschap ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Mouse Model

scholarly journals Autoregulation of Cerebral Blood Flow to Changes in Arterial Pressure in Mild Alzheimer's Disease

2010 ◽  
Vol 30 (11) ◽  
pp. 1883-1889 ◽  
Author(s):  
Allyson R Zazulia ◽  
Tom O Videen ◽  
John C Morris ◽  
William J Powers
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Arterial Pressure ◽  
The Elderly ◽  
Local Defect ◽  
Clinical Dementia Rating ◽  
Positron Emission ◽  
Before And After

Studies in transgenic mice overexpressing amyloid precursor protein (APP) demonstrate impaired autoregulation of cerebral blood flow (CBF) to changes in arterial pressure and suggest that cerebrovascular dysfunction may be critically important in the development of pathological Alzheimer's disease (AD). Given the relevance of such a finding for guiding hypertension treatment in the elderly, we assessed autoregulation in individuals with AD. Twenty persons aged 75±6 years with very mild or mild symptomatic AD (Clinical Dementia Rating 0.5 or 1.0) underwent 15O-positron emission tomography (PET) CBF measurements before and after mean arterial pressure (MAP) was lowered from 107±13 to 92±9 mm Hg with intravenous nicardipine; 11C-PIB-PET imaging and magnetic resonance imaging (MRI) were also obtained. There were no significant differences in mean CBF before and after MAP reduction in the bilateral hemispheres (−0.9±5.2 mL per 100 g per minute, P=0.4, 95% confidence interval (CI)=−3.4 to 1.5), cortical borderzones (−1.9±5.0 mL per 100 g per minute, P=0.10, 95% CI=−4.3 to 0.4), regions of T2W-MRI-defined leukoaraiosis (−0.3±4.4 mL per 100 g per minute, P=0.85, 95% CI=−3.3 to 3.9), or regions of peak 11C-PIB uptake (−2.5±7.7 mL per 100 g per minute, P=0.30, 95% CI=−7.7 to 2.7). The absence of significant change in CBF with a 10 to 15 mm Hg reduction in MAP within the normal autoregulatory range demonstrates that there is neither a generalized nor local defect of autoregulation in AD.

Regional Cerebral Blood Flow and Prognostic Evaluation in Alzheimer’s Disease

2001 ◽  
Vol 12 (2) ◽  
pp. 89-97 ◽  
Author(s):  
Flavio Nobili ◽  
Francesco Copello ◽  
Ferdinando Buffoni ◽  
Paolo Vitali ◽  
Nicola Girtler ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Regional Cerebral Blood Flow ◽  
Regional Cerebral Blood ◽  
Prognostic Evaluation

P4-305: IMPACT OF SIMVASTATIN ON CEREBRAL BLOOD FLOW, PULSATILITY INDEX, AND ALZHEIMER'S DISEASE BIOMARKERS: A CLINICAL TRIAL

2006 ◽  
Vol 14 (7S_Part_30) ◽  
pp. P1571-P1571
Author(s):  
Natanya S. Russek ◽  
Sara Elizabeth Berman ◽  
Karen K. Lazar ◽  
Yue Ma ◽  
Carson A. Hoffman ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Pulsatility Index ◽  
Disease Biomarkers ◽  
Flow Pulsatility
Sign in / Sign up

Export Citation Format

Share Document